Prosecution Insights
Last updated: November 04, 2026
Application No. 17/626,205

COMPOSITIONS AND METHODS FOR TREATING ALZHEIMERS DISEASE

Final Rejection §103§112§DOUBLEPATENT
Filed
Jan 11, 2022
Priority
Jul 12, 2019 — provisional 62/873,566 +2 more
Examiner
RODRIGUEZ-GARCIA, VALERIE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Meganano Biotech Inc.
OA Round
2 (Final)
69%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allowance Rate
575 granted / 834 resolved
+8.9% vs TC avg
Strong +32% interview lift
Without
With
+31.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
37 currently pending
Career history
876
Total Applications
across all art units

Statute-Specific Performance

§101
3.0%
-37.0% vs TC avg
§103
22.2%
-17.8% vs TC avg
§102
22.5%
-17.5% vs TC avg
§112
38.5%
-1.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 834 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Receipt of claim amendments and arguments filed on July 30, 2026 is acknowledged. Claims 51-66 are newly added. Thus, claims 25, 27, 30-31, 36-37 and 51-66 are currently pending. Applicant previously elected Group II, claims 25, 27, 30-31 and 36-37, drawn to a method of treating Alzheimer’s disease comprising administering a composition comprising tetrahydrocannabinol (THC), melatonin, and insulin, or a pharmaceutically acceptable salt of any of the foregoing; and at least one excipient. Withdrawn claims have been canceled. Claimed Priority PNG media_image1.png 64 566 media_image1.png Greyscale Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120 as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of 35 U.S.C. 112(a) or the first paragraph of pre-AIA 35 U.S.C. 112, except for the best mode requirement. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). In the instant case, the disclosure of the provisional application 62/873,566, fails to provide adequate support or enablement in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for one or more claims of this application. Accordingly, claims 25, 27, 30-31, 36-37 and 51-66, are not entitled to the benefit of the provisional application since particular embodiments of the claims are not supported by the original disclosure of the prior-filed application. Compositions used in the method, such as that of Example 1 and nanoemulsion preparations, were not described in the provisional application. The compositions/preparations encompassed by the claims are particularly those embodiments that are disclosed in the specification of this application. Introduction of examples and nanoemulsion preparations affects the claims. Thus, the provisional application does not support current embodiments that are disclosed in the application and encompassed by the breadth of the claims. Thus, the effective filing date of claims 25, 27, 30-31, 36-37 and 51-66 is the filling date of PCT/US20/41719, which is July 10, 2020. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claims 25, 27, 30-31, 36-37 and 51-66 are the subject of this Final Office Action. Rejections and objections not reiterated herein have been withdrawn. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 25, 27(amended), 30-31 and 36-37 remain rejected under 35 U.S.C. 103 as being unpatentable over Mukunda (WO2019/190608A1) and Cao (Journal of Alzheimer’s Disease 42 (2014) 973-984-cited by applicant in the IDS of 04/06/2022), in view of Craft (Arch Neurol. 2012 January; 69(1): 29-38), Wermeling (US 2007/0060639) and Sood (J. Drug Target, 2014; 22(4); 279-294). Applicant’s Invention The rejected claims are drawn to a method of treating Alzheimer’s disease with a composition comprising a combination of tetrahydrocannabinol (THC), melatonin, and insulin, and at least one excipient. Mukunda Mukunda teaches a method of treatment of Alzheimer’s disease using a composition comprising a combination of THC (tetrahydrocannabinol), melatonin and curcumin with excipients (see page 10). For example, THC and melatonin are administered in a dose as in paragraph [0056]: PNG media_image2.png 204 630 media_image2.png Greyscale THC is administered in a dose from about 0.2 µg/kg to about 0.14 mg/kg of body weight, preferably from about 0.2 µg/kg to about 0.03 mg/kg of body weight, per paragraph [0051] at page 13. With respect to amended claim 27, a THC dose amount of 0.03 mg/kg of body weight taught by Mukunda is a THC dose amount of 30 µg/kg of body weight. Particularly, Mukunda taught for an oral suspension, a dose that comprises 2.5 mg of THC for a 70-kg patient, which is a dose of 35.71 µg/kg; and other particular dose examples of 1.5 mg (21 µg/kg) of THC. See para [0048] and examples. Note that Mukunda considers an ultra-low dose to be from about 14 µg to about 2.0 mg (2,000 µg) per 70kg patient. Melatonin is administered in dose ranges from about 0.02 mg/kg to about 0.3 mg/kg of body weight, preferably from about 0.01 mg/kg to about 0.15 mg/kg of body weight (p. 13-14). Other melatonin doses disclosed are PNG media_image3.png 50 622 media_image3.png Greyscale and an amount per 70kg patient of form about 14 µg to about 77.0 mg (pages 10-11). They are combined in an oral suspension to be given once a day, twice a day, thrice a day or four times a day depending on the severity of the symptoms. Oral formulations are made in an ethanol/water mixture (see examples). Mukunda does not teach insulin. Cao Cao teaches that THC is effective at lowering Aβ levels at extremely low concentrations by interacting directly with Aβ peptide and inhibiting aggregation, and could be useful in the treatment of Alzheimer’s disease. Additionally, low doses of THC can enhance mitochondria function and does not inhibit melatonin’s enhancement of mitochondria function. In addition, the reference teaches: PNG media_image4.png 729 720 media_image4.png Greyscale . Craft Craft discloses that in clinical trials, intranasal insulin treatment improves memory in both Alzheimer’s patients and adults with aMCI. Craft teaches that insulin modulates the levels of Aβ and protects against the detrimental effects of Aβ oligomers on synapses. Regarding the benefits of intranasal administration, Craft discloses that it provides rapid delivery of insulin to the central nervous system via bulk flow along olfactory and trigeminal perivascular channels, and slower delivery via olfactory bulb axonal transport, without adversely affecting blood insulin or glucose levels. Intranasal insulin increases insulin levels in cerebrospinal fluid (CSF) and acutely enhances memory in humans. Intranasal insulin was administered at doses of 20 IU (10 IU twice a day) or 40 IU (20 IU twice a day). Craft does not teach THC or melatonin. Wermeling Wermeling teaches compositions for the intranasal administration of THC with the advantages of rapid and controlled absorption and consistent bioavailability. The compositions are to be used in the treatment of conditions associated with CNS disfunction, such as Alzheimer’s disease. See whole document. Wermeling does not teach melatonin or insulin. Sood Sood discusses the benefits of intranasal therapeutic strategies for the management of Alzheimer’s disease. Intranasal delivery provides fast onset of action, avoidance of the intestinal and hepatic presystemic disposition, reduction of systemic exposure and side effects with direct delivery and targeting to the brain and CSF, practicality and ease of administration and better patient compliance. It allows for the administration of lower doses and in return reduce their side effects. (See page 282) Sood teaches that melatonin protects neurons against Aβ toxicity and inhibits the progressive formation of β-sheets and amyloid fibrils; however, it has low oral BA, short biological half-life and erratic pharmacokinetic profile. They have found that intranasal (IN) administration of melatonin enhances drug absorption (see page 290). Sood additionally teaches that IN insulin improves memory, attention and function in Alzheimer patients (see page 288). Sood does not teach THC. Further, Sood concluded the following: PNG media_image5.png 219 341 media_image5.png Greyscale . Finding of prima facie obviousness--rational and motivation The Supreme Court in KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 415-421, 82 USPQ2d 1385, 1395-97 (2007) identified a number of rationales to support a conclusion of obviousness which are consistent with the proper "functional approach" to the determination of obviousness as laid down in Graham. See MPEP 2143. Examples of rationales that may support a conclusion of obviousness include: (A) Combining prior art elements according to known methods to yield predictable results; (B) Simple substitution of one known element for another to obtain predictable results; (C) Use of known technique to improve similar devices (methods, or products) in the same way; (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results; (E) "Obvious to try" – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success; (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art; (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. Applying KSR exemplary rationale (A), it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to treat Alzheimer’s disease with an intranasal composition of a combination of THC, melatonin and insulin, together with at least one excipient. Each agent was taught in the prior art to be used for treating Alzheimer’s disease. The advantages of their intranasal administration were also disclosed by the references. A person having ordinary skill would have had a reasonable expectation that administering an intranasal combination of the three anti-Alzheimer’s drugs and excipient would effectively treat Alzheimer’s disease in a patient. It has been held that “It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art.” In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). MPEP 2144.06. With respect to claims 27, 30, 31 and 36, it would have been prima facie obvious to exemplify any of the doses from about 0.2 µg to about 0.14 mg/kg of body weight of THC as taught by Mukunda, particularly, the preferred doses that comprises 2.5 mg of THC for a 70-kg patient, which is a dose of 35.71 µg/kg, and of 1.5 mg, which is a dose of 21 µg/kg of THC; any of doses of melatonin of from about 0.02 mg to about 0.3 mg/kg of body weight as taught by Mukunda (1.5 mg) (or references in Sood); and any of the IN insulin doses taught by Craft (20 IU or 40IU per dose) with a reasonable expectation of success. That is because the references teach that these are effective doses for treating AD and its symptoms. Additionally, the dose administered to the AD patient is considered a result-effective variable that impacts the effectiveness of the treatment. See for example the various doses researched/tested in the references. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). In addition, it would have been obvious to administer the composition once a day (24h intervals), twice a day, thrice a day or four times a day depending on the severity of the symptoms, because Mukunda taught so. Also, because the dosing intervals (i.e., 6 hour intervals, etc.) is considered a result-effective variable that impacts the effectiveness of the treatment. Differences in result-effective variables will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating the value of the result-effective variable is critical. See MPEP 2144.05. Applicant’s arguments were carefully considered but were found unpersuasive. Applicant first argues about the references individually. In response, the clear teachings of Mukunda, Cao, Craft, Wermeling and Sood were discussed above. The rejection here is based on the combination of references. Applicant alleges that the examiner's conclusion of obviousness is based upon improper hindsight reasoning. In response, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See In re McLaughlin, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). Most of Applicant’s arguments are related to doses/dosing. It is noted that Applicant’s arguments directed to doses are irrelevant to the obviousness rejection of claims that do not contain a dose. Applicant argues that the examiner did not provide evidence that the claimed doses are “result-effective variables”. First, it is noted that claims 25, 36 and 37 do not claim a dose. Second, it is noted that the examiner showed that the dose ranges disclosed in Mukunda contain the THC doses claimed; moreover, that the preferred THC doses disclosed in Mukunda anticipate the THC doses claimed, and that Craft taught the same doses of insulin claimed. Since the claimed doses were already disclosed in the prior art, it is not necessary to show that claimed doses are result-effective variables. Third, the references used in the rejection provide evidence that the dose of each active agent is a result- effective variable. For example, Cao taught that particular THC dosing affects the outcome in the treatment of Alzheimer’s disease. Mukunda taught THC and melatonin doses as variables in relation to Alzheimer’s treatment. Further, Craft provided insulin dose-response experiments involving human AD administration. In addition, Craft disclosed: “We have demonstrated previously in an acute-dosing study12 that the insulin-dose response curve for memory is characterized by a ∩-shaped function, in which beneficial effects are observed at optimal levels, and null or negative effects are observed when levels are too low or too high.” Further, Wermeling also tested different THC doses while disclosing at paragraphs [0064]-[0065] that: What constitutes an appropriate daily dose for a human subject depends on a variety of factors, including the particular cannabinoid in the composition and its bioavailability, the age, sex, and body weight of the subject, the condition being treated, and the severity of that condition. In the case of a psychotropic cannabinoid such as Δ9-THC, a dosage amount and frequency that minimizes psychotropic effects while providing therapeutic benefit can be selected by one of skill in the art without undue experimentation. Applicant further argues that THC as described in both Cao and Mukunda, is psychoactive at higher doses, and that a person of ordinary skill would be discouraged from following the path set out in Mukunda given a warning from Cao and Mukunda. Applicant’s argument is unpersuasive because the references disclose what the reasonable doses of THC are that will not produce psychoactive effects. Applicant further, alleges that the prior art teaches away from combining the teachings of the references because “Mukunda teaches an ultra-low dose of THC starting at 14µg for a 70 kg patient” and “the art’s express and implicit caution against higher THC exposure.” This cannot be found persuasive because Mukunda disclosed PNG media_image6.png 166 618 media_image6.png Greyscale And particularly, disclosed doses of 2.5mg and 1.5mg for a 70-kg patient that are effective and can be administered safely. Applicant further argues that they obtained unexpected results because the instant invention permits administration of materially higher THC doses in combination with melatonin and insulin without the adverse outcomes the art associates with THC escalation. This cannot be found persuasive because Mukunda disclosed doses of THC that will not produce psychoactive effects, such as 2.5mg and 1.5mg for a 70-kg patient that are effective and can be administered safely. Applicant argues that: PNG media_image7.png 80 578 media_image7.png Greyscale However, the rejection is based upon the teachings of a combination of references. It is the examiner’s position that the combination of references teach that THC, insulin and melatonin improve symptoms and function in Alzheimer’s disease patients without psychological deterioration, because the individual references teach that THC, insulin and melatonin improve symptoms and function in Alzheimer’s disease patients without recording any deterioration. The difference between the teachings of Mukunda and the rejected claims is that Mukunda does not teach insulin in their formulation. However, references above demonstrate the benefits of insulin formulations in the treatment of Alzheimer’s disease. Regarding the statement of results that are shown in the figures in the specificaton, Applicant has not shown a comparison with the closest prior art. See MPEP 716.02. Applicant alleges that a person of ordinary skill in the art would expect that co-administration of THC and insulin would increase safety risk, not reduce it. This allegation is unfounded. Applicant has not provided a reference teaching that the combination of the two ingredients would be unwanted. The references above are evidence that THC at the disclosed doses and insulin at the disclosed doses are beneficial and safe to treat patients with Alzheimer’s disease. For the ordinary skilled artisan at the time of filing, their combination would be expected to be similarly beneficial. “It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art.” In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). MPEP 2144.06. Again, there is no evidence in the record that the combination of the two ingredients would be unwanted. Further, in Mukunda, combinations of THC with other active ingredients, such as with melatonin, have also been found to be efficacious and safe. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 25, 27, 30-31, 36-37, 51, 54, 57, 58, 63 and 65 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 11,065,225 in view of Craft (Arch Neurol. 2012 January; 69(1): 29-38), Wermeling (US 2007/0060639) and Sood (J. Drug Target, 2014; 22(4); 279-294). The claims of the patent do not teach insulin. The claims of the patent teach administering THC in an ultra-low dose amount of PNG media_image8.png 17 218 media_image8.png Greyscale . Craft Craft discloses that in clinical trials, intranasal insulin treatment improves memory in both Alzheimer’s patients and adults with aMCI. Craft teaches that insulin modulates the levels of Aβ and protects against the detrimental effects of Aβ oligomers on synapses. Regarding the benefits of intranasal administration, Craft discloses that it provides rapid delivery of insulin to the central nervous system via bulk flow along olfactory and trigeminal perivascular channels, and slower delivery via olfactory bulb axonal transport, without adversely affecting blood insulin or glucose levels. Intranasal insulin increases insulin levels in cerebrospinal fluid (CSF) and acutely enhances memory in humans. Intranasal insulin was administered at doses of 20 IU (10 IU twice a day) or 40 IU (20 IU twice a day). Wermeling Wermeling teaches compositions for the intranasal administration of THC with the advantages of rapid and controlled absorption and consistent bioavailability. The compositions are to be used in the treatment of conditions associated with CNS disfunction, such as Alzheimer’s disease. See whole document. In addition, Wermeling teaches [0032] A composition adapted for intranasal administration according to the invention is of particular interest for a tricyclic cannabinoid that is psychotropic above a threshold systemic plasma concentration. Δ9-THC is an example of such a cannabinoid. It is believed that intranasal administration, by avoiding a high initial spike in plasma cannabinoid concentration, as occurs for example when the drug is administered intravenously or to a lesser extent when the drug is absorbed by smoking marihuana, while at the same time avoiding first-pass metabolism, as occurs when the drug is administered orally, can minimize psychotropic side-effects while maintaining a therapeutically effective plasma concentration for several hours. [0033] Δ9-THC is a highly hydrophobic compound with an octanol-water partition coefficient of about 6000:1 at pH 7. In view of such hydrophobicity and the fact in that the present composition the cannabinoid is in solubilized form, a solubilizing agent is a critical component. The solubilizing agent can comprise a solvent system for the cannabinoid, and this solvent system, itself comprising one or more solvents, can form the bulk of the medium in which the cannabinoid is dissolved. In another embodiment, the composition is in the form of an emulsion or microemulsion wherein the cannabinoid is in solution in a solvent system, for example sesame oil and/or other plant oils, which in turn is emulsified in an aqueous medium in the presence of one or more amphiphilic agents. [0036] Suitable solubilizing agents for a hydrophobic tricyclic cannabinoid such as Δ9-THC include pharmaceutically acceptable glycols. Examples of glycols include but are not limited to propylene glycol, 1,3-butanediol, polyethylene glycol, propylene glycol fatty acid esters, diethylene glycol monoethyl ether and mixtures thereof. Optionally, the solubilizing agent can further comprise ethanol. For example, propylene glycol and ethanol can be present in a volume ratio of at least about 80:20, for example at least about 90:10 or at least about 95:5. According to other embodiments, the solubilizing agent is essentially free of ethanol. [0037] When a hydrophobic tricyclic cannabinoid is present in an aqueous medium, the solubilizing agent can comprise at least one amphiphilic compound in an amount effective to solubilize the cannabinoid in the aqueous medium. For example, the at least one amphiphilic compound can be a cationic, anionic or nonionic surfactant. Illustrative amphiphilic compounds are benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, dioctyl sodium sulfosuccinate, nonoxynol 9, nonoxynol 10, octoxynol 9, poloxamers, polyoxyethylene (8) caprylic/capric mono- and diglycerides, polyoxyethylene (35) castor oil, polyoxyethylene (20) cetostearyl ether, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (10) oleyl ether, polyoxyethylene (40) stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, propylene glycol laurate, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate and tyloxapol, or mixtures thereof. Wermeling does not teach melatonin or insulin. Sood Sood discusses the benefits of intranasal therapeutic strategies for the management of Alzheimer’s disease. Intranasal delivery provides fast onset of action, avoidance of the intestinal and hepatic presystemic disposition, reduction of systemic exposure and side effects with direct delivery and targeting to the brain and CSF, practicality and ease of administration and better patient compliance. It allows for the administration of lower doses and in return reduce their side effects. Factors influencing mucoadhesion include pH (see page 282). At page 284 Sood teaches that a strategy that has been investigated for enhancing the absorption and thereby the BA of nasally administered drugs includes nanoemulsions. See Figure 3 and various drugs disclosed therein. Sood teaches that melatonin protects neurons against Aβ toxicity and inhibits the progressive formation of β-sheets and amyloid fibrils; however, it has low oral BA, short biological half-life and erratic pharmacokinetic profile. They have found that intranasal (IN) administration of melatonin enhances drug absorption (see page 290). Sood additionally teaches that intranasal (IN) insulin improves memory, attention and function in Alzheimer patients (see page 288), and cites references as evidence and that assessed different doses of IN insulin. Further, Sood concluded the following: PNG media_image5.png 219 341 media_image5.png Greyscale . Sood does not teach THC. Finding of prima facie obviousness--rational and motivation The Supreme Court in KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 415-421, 82 USPQ2d 1385, 1395-97 (2007) identified a number of rationales to support a conclusion of obviousness which are consistent with the proper "functional approach" to the determination of obviousness as laid down in Graham. See MPEP 2143. Examples of rationales that may support a conclusion of obviousness include: (A) Combining prior art elements according to known methods to yield predictable results; (B) Simple substitution of one known element for another to obtain predictable results; (C) Use of known technique to improve similar devices (methods, or products) in the same way; (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results; (E) "Obvious to try" – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success; (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art; (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. Applying KSR exemplary rationale (A), it would have been prima facie obvious to one of ordinary skill in the art to treat Alzheimer’s disease with a composition of a combination of THC and melatonin at the doses recited in the patented claims, in combination with insulin at the dose taught in the references and at least one excipient. Each combination was taught in the prior art to be used for treating Alzheimer’s disease. Further, the advantages of intranasal administration of each ingredient were disclosed by the references. Thus, a person having ordinary skill would have had a reasonable expectation that administering an intranasal combination of THC and melatonin at the doses recited in the patented claims, together with a dose of insulin recited in the references and excipient, would effectively treat Alzheimer’s disease in a patient. It has been held that “It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art.” In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). MPEP 2144.06. The same doses of THC and melatonin and administration intervals as claimed here are recited in the patented claims. Regarding the new dose of at least 1 µg/kg of claim 27, the prior art teaches THC in an ultra-low dose amount of PNG media_image8.png 17 218 media_image8.png Greyscale , which substantially overlaps with the at least 1µg/kg instantly claimed. It is noted that the courts have stated where the claimed ranges “overlap or lie inside the ranges disclosed by the prior art” and even when the claimed ranges and prior art ranges do not overlap but are close enough that one skilled in the art would have expected them to have similar properties, a prima facie case of obviousness exists (see In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990); Titanium Metals Corp. of America v. Banner, 778 F2d 775. 227 USPQ 773 (Fed. Cir. 1985) (see MPEP 2144.05.01). The courts have also found that, “where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). See MPEP 2144.05 II. Therefore, the claimed range merely represents an obvious variant and routine optimization of already disclosed range within the prior art. Applicant’s arguments were carefully considered but were found unpersuasive. Applicant reiterated the arguments above, and those have been already discussed. Regarding the argument about the doses in the ‘225 patent, and how “the doses extend up to about 0.16mg/kg with the express goal of remaining below doses associated with psychological impairment”, when converted into micrograms, the doses extend up to 160 µg/kg which are within the scope of the claims. Applicant’s claim 27 recites a dose of at least 1 µg/kg, and thus, it is unclear how applicant argues that the dose is critical if their claimed dose starts at 1 µg/kg and has no upper limit. Further, it is unclear how applicant argues that one of ordinary skill would be diverted from using doses of THC which are currently claimed when the same doses have been disclosed and suggested as useful and safe in the patent. Nothing in the references suggest that the combination of THC and melatonin of the patent should not be combined with insulin of the secondary references. New grounds of rejection necessitated by the claim amendments Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 51-55 and 57-66 are rejected under 35 U.S.C. 103 as being unpatentable over Mukunda (WO2019/190608A1) in view of Craft (Arch Neurol. 2012 January; 69(1): 29-38), Wermeling (US 2007/0060639) and Sood (J. Drug Target, 2014; 22(4); 279-294) as applied to claims 25, 27, 30-31 and 36-37 above, and further in view of Sigurdsson et al. ((1997). Drug Delivery, 4(3), 195–200- for claim 55), Sintov et al. (J. Controlled Release 2010, 148 (2), 168-176) and Watts (US 6,383,513), and as evidence for claims 61-63 are Tripathy (Nanomedicine; NBM 2016; 12:1431-1443) or Shakeel (Pharm. Devel. Tech., 2010; 15(2): 131-138) or Khatoon (Drug Delivery and Translational Research (2021) 11:1245-1260). Applicant’s Invention The rejected claims are drawn to a method of treating Alzheimer’s disease with a composition comprising a combination of tetrahydrocannabinol (THC), melatonin, and insulin, and at least one excipient. Mukunda Mukunda teaches a method of treatment of Alzheimer’s disease using a composition comprising a combination of THC (tetrahydrocannabinol), melatonin and curcumin with excipients (see page 10). THC is administered in a dose amount from about 0.2 µg/kg to about 0.14 mg/kg of body weight, preferably in an ultra-low dose from about 0.2 µg/kg to about 0.03 mg/kg of body weight (see page 13, paragraph [0051]). With respect to amended claim 27 and new claims 51 and 64, a THC dose amount of 0.03 mg/kg of body weight taught by Mukunda is a THC dose amount of 30 µg/kg of body weight. Also with respect to the THC doses in claims 27, 51, 52, 53 and 64, Mukunda teaches doses of about 14 µg to about 10.0 mg of THC, preferably 14 µg to about 2.0 mg of THC. See paragraph [0035]. Mukunda discloses specific examples falling within the claimed ranges. Particularly, Mukunda taught for an oral suspension, a dose that comprises 2.5 mg of THC for a 70-kg patient, which is a dose of 35.71 µg/kg; and other particular dose examples of 1.5 mg (21 µg/kg) of THC. See para [0048] and examples. Note that Mukunda considers an ultra-low dose to be from about 14 µg to about 2.0 mg (2,000 µg) per 70kg patient. Also, in Example 1 at page 17, one dose of the liquid formulation comprises: PNG media_image9.png 92 624 media_image9.png Greyscale . Thus, Mukunda also teaches a formulation with a dose of 1.5 mg THC and 1.5 mg melatonin, for a ratio of 1:1 as in new claim 66. With regards to 57-60 and 64, in Example 9 Mukunda teaches an emulsion containing the same dose of THC and melatonin (1.5 mg each (1:1) -see Example 1), also containing a nonionic emulsifier “preferably added to increase the solubility of THC” and other active ingredients in the solution, which nonionic emulsifiers include lecithin, polysorbate 80 (is also a surfactant), and vitamin E TPGS. A preferred emulsifier is a combination of polysorbate-80 and Vitamin E TPGS. See page 9 and Example 10. Thus, Mukunda also teaches emulsion formulations as in claims 57-58 and 64, in which the organic phase comprises lecithin or Vitamin E TPGS as in new claim 59, and the emulsifier comprises polysorbate-80, as in new claim 60. With regards to new claim 65, Mukunda teaches that THC is PNG media_image10.png 26 180 media_image10.png Greyscale , which is Dronabinol. They also teach PNG media_image11.png 84 620 media_image11.png Greyscale Melatonin is administered in dose ranges from about 0.02 mg/kg to about 0.3 mg/kg of body weight, preferably from about 0.01 mg/kg to about 0.15 mg/kg of body weight (p. 13-14). Other melatonin doses disclosed are PNG media_image3.png 50 622 media_image3.png Greyscale and an amount per 70kg patient of form about 14 µg to about 77.0 mg (pages 10-11). They are combined in an oral suspension to be given once a day, twice a day, thrice a day or four times a day depending on the severity of the symptoms. Oral formulations are made in an ethanol/water mixture (see examples). Mukunda does not teach insulin. Craft The teachings of Craft were discussed in the previous rejection. Wermeling Wermeling teaches compositions for the intranasal administration of THC with the advantages of rapid and controlled absorption and consistent bioavailability. The compositions are to be used in the treatment of conditions associated with CNS disfunction, such as Alzheimer’s disease. See whole document. In addition, Wermeling teaches [0032] A composition adapted for intranasal administration according to the invention is of particular interest for a tricyclic cannabinoid that is psychotropic above a threshold systemic plasma concentration. Δ9-THC is an example of such a cannabinoid. It is believed that intranasal administration, by avoiding a high initial spike in plasma cannabinoid concentration, as occurs for example when the drug is administered intravenously or to a lesser extent when the drug is absorbed by smoking marihuana, while at the same time avoiding first-pass metabolism, as occurs when the drug is administered orally, can minimize psychotropic side-effects while maintaining a therapeutically effective plasma concentration for several hours. [0033] Δ9-THC is a highly hydrophobic compound with an octanol-water partition coefficient of about 6000:1 at pH 7. In view of such hydrophobicity and the fact in that the present composition the cannabinoid is in solubilized form, a solubilizing agent is a critical component. The solubilizing agent can comprise a solvent system for the cannabinoid, and this solvent system, itself comprising one or more solvents, can form the bulk of the medium in which the cannabinoid is dissolved. In another embodiment, the composition is in the form of an emulsion or microemulsion wherein the cannabinoid is in solution in a solvent system, for example sesame oil and/or other plant oils, which in turn is emulsified in an aqueous medium in the presence of one or more amphiphilic agents. [0036] Suitable solubilizing agents for a hydrophobic tricyclic cannabinoid such as Δ9-THC include pharmaceutically acceptable glycols. Examples of glycols include but are not limited to propylene glycol, 1,3-butanediol, polyethylene glycol, propylene glycol fatty acid esters, diethylene glycol monoethyl ether and mixtures thereof. Optionally, the solubilizing agent can further comprise ethanol. For example, propylene glycol and ethanol can be present in a volume ratio of at least about 80:20, for example at least about 90:10 or at least about 95:5. According to other embodiments, the solubilizing agent is essentially free of ethanol. [0037] When a hydrophobic tricyclic cannabinoid is present in an aqueous medium, the solubilizing agent can comprise at least one amphiphilic compound in an amount effective to solubilize the cannabinoid in the aqueous medium. For example, the at least one amphiphilic compound can be a cationic, anionic or nonionic surfactant. Illustrative amphiphilic compounds are benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, dioctyl sodium sulfosuccinate, nonoxynol 9, nonoxynol 10, octoxynol 9, poloxamers, polyoxyethylene (8) caprylic/capric mono- and diglycerides, polyoxyethylene (35) castor oil, polyoxyethylene (20) cetostearyl ether, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (10) oleyl ether, polyoxyethylene (40) stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, propylene glycol laurate, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate and tyloxapol, or mixtures thereof. Wermeling does not teach melatonin or insulin. Sood Sood discusses the benefits of intranasal therapeutic strategies for the management of Alzheimer’s disease. Intranasal delivery provides fast onset of action, avoidance of the intestinal and hepatic presystemic disposition, reduction of systemic exposure and side effects with direct delivery and targeting to the brain and CSF, practicality and ease of administration and better patient compliance. It allows for the administration of lower doses and in return reduce their side effects. Factors influencing mucoadhesion include pH (see page 282). At page 284 Sood teaches that a strategy that has been investigated for enhancing the absorption and thereby the BA of nasally administered drugs includes nanoemulsions. See Figure 3 and various drugs disclosed therein. Sood teaches that melatonin protects neurons against Aβ toxicity and inhibits the progressive formation of β-sheets and amyloid fibrils; however, it has low oral BA, short biological half-life and erratic pharmacokinetic profile. They have found that intranasal (IN) administration of melatonin enhances drug absorption (see page 290). Sood additionally teaches that intranasal (IN) insulin improves memory, attention and function in Alzheimer patients (see page 288), and cites references as evidence and that assessed different doses of IN insulin. Further, Sood concluded the following: PNG media_image5.png 219 341 media_image5.png Greyscale . Sood does not teach THC. Sigurdsson Sigurdson teaches that intranasal formulations containing insulin at a pH between 5.5 and 6.5 reaches maximum absorption with a significantly greater amount absorbed at pH 6.5 than at pH 7.5. Thus, the artisan knew that the best pH of intranasal formulations containing insulin is about 6.5 See page 197: PNG media_image12.png 122 352 media_image12.png Greyscale . Sintov Intranasal insulin W/O nano-sized emulsions (conventionally called microemulsions- see page 169) with average droplet size of 2.26 nm in diameter have been prepared by Sintov. The acceleration in the intramucosal transport process is the result of encapsulating insulin within the nano-droplet clusters. See Abstract. Note all the ingredients used for the emulsion, such as aqueous phase, emulsifier, and oils. Watts Watts disclosed: The nasal route is known to provide advantages for the delivery of drugs, and for some drugs the pharmacokinetic profile following nasal administration is similar to that found after intravenous administration. However, THC is in the form of an oily liquid which is highly lipid soluble and only sparingly soluble in water. Hence, the person skilled in the art would consider it impossible to produce a simple nasal solution or other simple gel or suspension formulation that could produce sufficient nasal absorption and therapeutic plasma levels. THC can be formulated successfully into a nasal product by using a biphasic delivery system and that such a biphasic delivery system provides improved nasal absorption and therapeutically relevant plasma levels. Compositions for the nasal delivery of THC in O/W emulsions of droplet sizes of 250 nm and about 280nm were prepared. Water, oil and emulsifiers are used, which are the same or similar to the ingredients of the other formulations in the references above. See column 3 and examples. Tripathy, Shakeel, Khatoon These references teach three actives accommodated in the same nanoemulsion formulation system and the design to produce nanoscale droplets while screening oils, surfactants, drug solubility, etc. Finding of prima facie obviousness--rational and motivation The Supreme Court in KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 415-421, 82 USPQ2d 1385, 1395-97 (2007) identified a number of rationales to support a conclusion of obviousness which are consistent with the proper "functional approach" to the determination of obviousness as laid down in Graham. See MPEP 2143. Examples of rationales that may support a conclusion of obviousness include: (A) Combining prior art elements according to known methods to yield predictable results; (B) Simple substitution of one known element for another to obtain predictable results; (C) Use of known technique to improve similar devices (methods, or products) in the same way; (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results; (E) "Obvious to try" – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success; (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art; (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. Applying KSR exemplary rationale (A), it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to treat Alzheimer’s disease with an intranasal formulation comprising THC, melatonin and insulin in an emulsion or nanoemulsion (with at least one excipient), at the THC doses taught by Mukunda ( 2.5 mg of THC for a 70-kg patient, which is a dose of 35.71 µg/kg; 1.5 mg, which is a dose of 21 µg/kg of THC; 1.5 mg or 2.0 mg of THC); the melatonin doses taught by Mukunda or references in Sood (e.g. 1.5 mg); and the IN insulin doses taught by Craft (20 IU or 40IU per dose), because the references teach that these are effective agents at said effective doses for treating AD and also teach that there are advantages in making emulsion/nanoemulsion formulations containing these agents for intranasal administration. Note the advantages disclosed by the references. The artisan knew what ingredients to select to make the emulsion/nanoemulsion, such as the type of oil and emulsifiers, which were taught by above references. All the teachings of the references provided a reasonable expectation of success. A person having ordinary skill would have been motivated to find optimal pH for the intranasal liquid emulsion/nanoemulsion because the artisan knew that the pH is a factor that influences mucoadhesion (per at least Sood). In addition, the artisan would have been aware that a pH of about 6.5 provides a significantly greater absorption of insulin (per Sigurdsson), thus, the artisan would have been motivated to make the formulation with a similar pH. Regarding the droplet size of the emulsion, the artisan would have been motivated to encapsulate THC, melatonin and insulin together in nanoemulsions of 2.26nm or 250 nm, and about 280nm droplet size, because the references teach that these parameters improve nasal absorption of the formulation and acceleration in the intramucosal transport process. See at least Sintov and Watts. There would have been a reasonable expectation of successfully incorporating THC, insulin and melatonin into a nasal nanoemulsion with the claim droplet size because encapsulation of three active agents in nanoemulsions at various droplet sizes was known in the art. See at least Tripathy, Shakeel and Khatoon. Applicant’s arguments have been responded to above. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 56, 64, 65 and 66 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 56 is ambiguous. Claim 56 depends of claim 54. Thus, claim 56 recites: “wherein the composition is formulated for intranasal administration in a liquid dosage form, wherein the liquid dosage form is encased in a capsule for oral administration.” It is unclear what the claim encompasses. This claim cannot be examined. Claim 64 recites: PNG media_image13.png 102 536 media_image13.png Greyscale The claim does not recite “the method of claim 25, wherein the composition comprises…”. The claim appears to claim both a process of using a composition and a composition, and this is indefinite. MPEP 2173.05(p) states that: II. PRODUCT AND PROCESS IN THE SAME CLAIM A single claim which claims both an apparatus and the method steps of using the apparatus is indefinite under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph. See In re Katz Interactive Call Processing Patent Litigation, 639 F.3d 1303, 1318, 97 USPQ2d 1737, 1748-49 (Fed. Cir. 2011). In Katz, a claim directed to "[a] system with an interface means for providing automated voice messages…to certain of said individual callers, wherein said certain of said individual callers digitally enter data" was determined to be indefinite because the italicized claim limitation is not directed to the system, but rather to actions of the individual callers, which creates confusion as to when direct infringement occurs. Katz, 639 F.3d at 1318, 97 USPQ2d at 1749 (citing IPXL Holdings v. Amazon.com, Inc., 430 F.3d 1377, 1384, 77 USPQ2d 1140, 1145 (Fed. Cir. 2005), in which a system claim that recited "an input means" and required a user to use the input means was found to be indefinite because it was unclear "whether infringement … occurs when one creates a system that allows the user [to use the input means], or whether infringement occurs when the user actually uses the input means."); Ex parte Lyell, 17 USPQ2d 1548 (Bd. Pat. App. & Inter. 1990) (claim directed to an automatic transmission workstand and the method of using it held ambiguous and properly rejected under 35 U.S.C. 112, second paragraph).[AltContent: rect] Claim 65 is ambiguous for the following reasons: 1- It recites that the THC is THC-A. THC is tetrahydrocannabinol of the following formulae: PNG media_image14.png 226 228 media_image14.png Greyscale and PNG media_image15.png 232 168 media_image15.png Greyscale . However, THC-A is tetrahydrocannabinolic acid: PNG media_image16.png 138 242 media_image16.png Greyscale . THC does not include THC-A. The specification of this application has not redefined the claim term. See MPEP 2173.05(a). 2- It recites that THC is Dronabinol. However, Dronabinol is a formulation containing additional ingredients (at least sesame oil) together with THC. The term THC in claim 25 does not encompass mixtures of ingredients outside of THC. Claim 66 is indefinite because it recites a ratio without describing if it is a mole ratio, a weight ratio or molarity ratio. Conclusion Claims 25, 27, 30-31, 36-37 and 51-66 are rejected. No claim is in condition for allowance. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to VALERIE RODRIGUEZ-GARCIA whose telephone number is (571)270-5865. The examiner can normally be reached Monday-Friday 9:30am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /VALERIE RODRIGUEZ-GARCIA/Primary Examiner, Art Unit 1621 08/22/2026
Read full office action

Prosecution Timeline

Jan 11, 2022
Application Filed
Apr 17, 2025
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT
Nov 01, 2025
Response after Non-Final Action
Jan 16, 2026
Response Filed
Jan 16, 2026
Response after Non-Final Action
Jul 30, 2026
Response Filed
Aug 26, 2026
Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780788
METHOD FOR PREPARING AZOXYSTROBIN AND INTERMEDIATE THEREOF
3y 4m to grant Granted Nov 03, 2026
Patent 12774288
4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF
4y 3m to grant Granted Oct 27, 2026
Patent 12774271
PROCESS FOR THE PRODUCTION OF LACTIDE
3y 4m to grant Granted Oct 27, 2026
Patent 12759993
PROCESS FOR REFINING GLYCOLIDE AND GLYCOLIDE OBTAINED THEREFROM
3y 5m to grant Granted Oct 13, 2026
Patent 12759986
CRYSTAL FORMS OF TETRAHYDRO-N, N-DIMETHYL-2, 2-DIPHENYL-3-FURANMETHANAMINE, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS
3y 5m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
69%
Grant Probability
99%
With Interview (+31.7%)
2y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 834 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month